drugset / Trial / NCT06640309
The Effect of Nicotinamide on the Clinical Outcome of Rheumatoid Arthritis Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
A randomized controlled interventional study to evaluate the efficacy and safety of nicotinamide supplementation in rheumatoid arthritis patients receiving conventional synthetic disease modifying anti-rheumatic drugs.
Timeline
- Start
- 2023-12-02
- Primary completion
- 2025-06
- Completion
- 2025-06
Publications
- Background Kamat JP, Devasagayam TP. Nicotinamide (vitamin B3) as an effective antioxidant against oxidative damage in rat brain mitochondria. Redox Rep. 1999;4(4):179-84. doi: 10.1179/135100099101534882.
- Background Miesel R, Kurpisz M, Kroger H. Modulation of inflammatory arthritis by inhibition of poly(ADP ribose) polymerase. Inflammation. 1995 Jun;19(3):379-87. doi: 10.1007/BF01534394.
- Background Ungerstedt JS, Blomback M, Soderstrom T. Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin Exp Immunol. 2003 Jan;131(1):48-52. doi: 10.1046/j.1365-2249.2003.02031.x.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nicotinamide | Other / unclassified | 1000 mg | — |
| Background | Hydroxychloroquine | Small molecule | — | — |
| Background | Leflunomide | Small molecule | — | — |
| Background | Methotrexate | Small molecule | — | — |
| Background | Sulfasalazine | Small molecule | — | — |